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Omalizumab has demonstrated therapeutic benefits in controlled clinical trials. Evaluation of
outcomes in real-world clinical practice is needed to provide a complete understanding of the
benefits of omalizumab treatment.
eXpeRience was a 2-year, international, single-arm, open-label, observational registry that
evaluated real-world effectiveness, safety and use of omalizumab therapy in 943 patients with
uncontrolled persistent allergic asthma. Effectiveness variables (physician’s Global Evaluation
of Treatment Effectiveness [GETE], and change from baseline in exacerbation rate, symptoms,
rescue medication use, and oral corticosteroid [OCS] use) were evaluated at pre-specified
time-points. Safety data were also recorded.
By physician’s GETE, 69.9% of patients were responders to omalizumab after 16 (1) weeks.
The proportion of patients with no clinically significant exacerbations increased from 6.8% dur-
ing the 12-month pre-treatment period to 54.1% and 67.3% at Months 12 and 24, respectively.
Symptoms and rescue medication use at Month 24 were reduced by >50% from baseline. Main-
tenance OCS use was lower at Month 24 (14.2%) compared with Month 12 (16.1%) and baseline
(28.6%). Overall, omalizumab had an acceptable safety profile.
The results from eXpeRience indicate that omalizumab was associated with improvements in
outcomes in patients with uncontrolled persistent allergic asthma; these improvements were
consistent with the results of clinical trials.
ª 2013 Elsevier Ltd. All rights reserved.461 6148; fax: þ31 10 461 2692.
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1142 G.-J. Braunstahl et al.Introduction would be sufficient to draw meaningful conclusions from
the registry. Recruitment was therefore stopped in OctoberOmalizumab is a humanised anti-immunoglobulin E (IgE)
monoclonal antibody licensed in the European Union for
patients aged 6 yrs with severe allergic asthma that is
inadequately controlled with inhaled corticosteroids (ICSs)
and long-acting b2-agonists (LABAs); and in the United
States for patients aged 12 yrs with moderate-to-severe
allergic asthma inadequately controlled with ICSs. Pa-
tients for whom omalizumab is indicated typically have a
high frequency of asthma symptoms and exacerbations,
impaired lung function and reduced quality of life.1
Although persistent asthma can often be controlled using
ICSs and LABAs, many patients with severe asthma remain
uncontrolled despite these therapies.1 Although asthma
control is often achieved in clinical trials, this is frequently
not the case in everyday clinical practice.2 Non-adherence
to treatment and poor inhaler technique are the main
factors that affect asthma control in real-world settings.3,4
Evaluation of outcomes in real-world clinical practice is
therefore necessary to supplement information from clin-
ical trials and to provide a more complete understanding of
the value of treatments for patients with asthma.
Numerous randomised clinical trials have shown that
adding omalizumab to current asthma therapy is effective
and well tolerated.5e14 Data from these clinical studies
have shown that add-on therapy with omalizumab signifi-
cantly reduces asthma exacerbations, ICS requirements and
emergency room (ER)/hospital visits versus placebo in pa-
tients with uncontrolled moderate-to-severe and severe
allergic asthma.5e14 To complement the efficacy and safety
data from these clinical trials, a 2-year, global, post-
marketing observational registry (eXpeRience) was initi-
ated. Its main purpose was to evaluate outcomes in pa-
tients receiving omalizumab for uncontrolled persistent
allergic asthma in ‘real-world’ clinical practice, and,
additionally, to review the nature and frequency of serious
adverse events (SAEs).Methods
The eXpeRience registry was an international, single-arm,
open-label, observational registry set up to facilitate the
collection of data from patients receiving omalizumab for
uncontrolled persistent allergic (IgE-mediated) asthma.
Patients from 14 countries in Europe, the Americas and Asia
were enrolled. The registry was not designed to test a
formal hypothesis. Treatment and follow-up of patients was
at the discretion of treating physicians, who followed local
medical practice and labelling/reimbursement guidelines.
The registry design was reviewed by independent ethics
committees or institutional review boards at each centre,
and the registry itself was conducted in accordance with
the Declaration of Helsinki. All patients provided informed
consent to participate.
The enrolment target of 1300 patients was flexible and
could vary, as no formal global sample size was specified,
and participating countries were permitted to enrol pa-
tients to meet local needs for information. However, an
interim review concluded that a minimum of 900 patients2009 when 943 patients had been enrolled.
Patients were eligible for inclusion if they met the local
labelling requirements for omalizumab use and had
commenced omalizumab within the previous 15 weeks.
Enrolment took place over an approximately 2.5-year
period, beginning in May 2006, and participants were fol-
lowed for up to 2 yrs after treatment initiation. Patients
were excluded if they were currently enrolled and receiving
treatment in a clinical trial of omalizumab or another
asthma medication, or if they had received omalizumab in
the past 18 months. The protocol was amended for Canada
to allow 20 participants from a prospective study of pa-
tients treated under real-world conditions (the XCEED
study)15 to be enrolled in the eXpeRience registry, despite
the fact that they may have started omalizumab more than
15 weeks before enrolment.
Upon enrolment, medical records were used to provide
baseline information on patients’ asthma status, asthma
control and healthcare utilisation during the year before
omalizumab initiation. No diagnostic or monitoring pro-
cedures were applied. After entry into the registry, data
on clinical symptoms, asthma control, lung function, ex-
acerbations, concomitant medication and status of
comorbidities were collected prospectively at approxi-
mately 16 weeks and at 8, 12, 18 and 24 months after
initiation of omalizumab treatment, with a minimum
requirement of two data collections per year. Patients
were removed from the registry if they withdrew con-
sent, if data collection was no longer possible due to the
patient not returning or being lost to follow-up, or if the
patient enrolled in a clinical study. Patients who dis-
continued omalizumab remained in the registry and were
followed up, wherever possible, for up to 2 yrs after
treatment initiation.
Registry assessments
Response to omalizumab was assessed using the physician’s
Global Evaluation of Treatment Effectiveness (GETE), an
overall clinical evaluation of asthma control at 16 weeks,
based on all available information: patient interview and
physical examination, and review of patient notes and diary
(if used). Following the Week 16 assessment, GETE was not
collected for the duration of the registry.16 Investigators
also assessed symptom control and performed spirometry
measurements before rating the effect of omalizumab on a
five-point scale, where 1 Z excellent (complete control of
asthma), 2 Z good (marked improvement), 3 Z moderate
(discernible, but limited improvement), 4 Z poor
(no appreciable change) and 5 Z worsening. Patients with
an ‘excellent’ or ‘good’ response were considered to be
responders.
Numbers of clinically significant and severe clinically
significant asthma exacerbations were recorded. Global
Initiative for Asthma (GINA) definitions were used17: clini-
cally significant exacerbations were defined as any wors-
ening of asthma considered by the treating physician to
require systemic corticosteroids, and were regarded as
severe if there was a reduction in peak expiratory flow
Table 1 Baseline demographics and clinical characteris-
tics (safety population).
Variable Value (N Z 925)
Age group, n (%)
<12 yrs 2 (0.2)
12e17 yrs 51 (5.5)
18e64 yrs 796 (86.1)
65 yrs 76 (8.2)
Age, yrs
Mean (SD) 45 (15.0)
Gender, n (%)
Male 325 (35.1)
Female 600 (64.9)
Race, n (%)
Caucasian 855 (92.4)
Asian 32 (3.5)
Black 21 (2.3)
Native American 2 (0.2)
Other 15 (1.6)
Body weight, kga
Mean (SD) 75.5 (17.7)
Baseline IgE level, IU/mLa
Mean (SD) 323.1 (460.9)
Range 8e7670f
Duration of allergic asthma, yrsb
Mean (SD) 19.4 (13.6)
Median 16.0
Positive skin-prick test/RAST
for perennial aeroallergens, n (%)a
816 (88.2)
Specificationc
Dust mites 698 (75.5)
Cat dander 327 (35.4)
Dog dander 300 (32.4)
Cockroaches 110 (11.9)
Other 103 (11.1)
History of allergy to seasonal
aeroallergens present, n (%)a
587 (63.5)
Smoking history, n (%)d
Never smoked 719 (77.7)
Ex-smoker 173 (18.7)
Current smoker 30 (3.2)
Asthma clinical symptoms (n Z 916)
Daytime asthma symptoms, n (%) 829 (90.5)
Limitations of activities, n (%) 788 (86.0)
Nocturnal symptoms/ 729 (79.6)
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Data on exacerbations were annualised; that is, for Month
12, rates were derived from Week 16, Month 8 and Month 12
data; for Month 24, rates were derived from data collected
at Months 18 and 24.
Investigators were provided with the Asthma Control
Test [ACT] and/or asthma control questionnaire (ACQ),
but were not required to use them. Where used, the ACT
and ACQ were generally routinely administered throughout
the evaluation period. The ACT assesses interference with
activities, shortness of breath, nocturnal symptoms, rescue
medication use, and self-rating of asthma control.18,19 The
overall score for each patient is the total of the responses
to the 5 questions, and ranges from 5 (poorly controlled
asthma) to 25 (well-controlled asthma). The minimum
important difference for the ACT has been defined as 3
points.19 The ACQ includes both patient-reported symptoms
and physician-determined forced expiratory volume in
1 s (FEV1).
20 In eXpeRience, the overall ACQ score was
calculated as the sum of individual item scores divided by
the number of questions answered at each time-point,
provided at least four questions were answered; other-
wise, no value was entered for that time-point. ACQ scores
range from 0 (completely controlled) to 6 (extremely poorly
controlled). A decrease in ACQ score of 0.5 points is
considered to be the minimal clinically important
improvement.21
Investigators were also provided with (but not obliged to
use) the standard 32-item Asthma Quality-of-Life Ques-
tionnaire (AQLQ) or the 15-item version (mini-AQLQ), both
of which are validated measures of functional impairment
in adults with asthma.22,23 An increase in AQLQ or mini-
AQLQ score of 0.5 points is considered to be the mini-
mal clinically important improvement.22,24
Other assessments included symptoms, use of rescue
medication, lung function (FEV1 and PEF), asthma-related
healthcare utilisation (hospitalisations, ER visits and un-
scheduled doctor visits), days of missed work or school, and
oral corticosteroid (OCS) use.
Data on serious adverse events (SAEs) were collected
during the registry. SAEs were defined as events that were
fatal or life-threatening, resulted in persistent or signifi-
cant disability/incapacity, or required inpatient hospital-
isation or prolongation of existing hospitalisation.
Information on SAEs, regardless of suspected causality, was
collected and reported within 24 h of the event’s occur-
rence. All SAEs were followed until resolution.awakenings, n (%)
Asthma controle (n Z 916)
Controlled, n (%) 13 (1.4)
Partly controlled, n (%) 209 (22.8)
Uncontrolled, n (%) 690 (75.3)
Unknown, n (%) 3 (0.3)
Missing, n (%) 1 (0.1)
IgE Z immunoglobulin E; RAST Z radioallergosorbent test;
SD Z standard deviation.
a Data missing for one patient.
b Data missing for 13 patients.
c Multiple entries possible.
d Data missing for three patients.
e Investigator’s assessment.
f Confirmed by the investigator.Statistical analysis
The primary effectiveness analysis was performed on the
intent-to-treat (ITT) population, which comprised all
enrolled patients who received at least one dose of oma-
lizumab and had at least one post-baseline effectiveness
assessment. Efficacy tables were also created for the per-
protocol (PP) population to assess the impact on the re-
sults of patients with at least one major protocol devia-
tion. The safety population comprised all patients who
were enrolled in the registry, received at least one dose of
omalizumab and had at least one post-baseline safety
assessment.
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ised using mean and standard deviation (SD), and fre-
quencies for discrete variables. Descriptive summaries are
presented for physician’s GETE, clinically significant
asthma exacerbations, FEV1 and PEF, ACT, ACQ, AQLQ and
mini-AQLQ scores, healthcare utilisation, and OCS use.Results
Baseline demographics and clinical characteristics are
shown in Table 1. Nine hundred and forty-three patients
were enrolled in the eXpeRience registry, of whom
694 (73.6%) completed 2 yrs of follow up (Fig. 1, patient
disposition). The ITT population comprised 916 patients;
27 patients were excluded due to absence of post-
baseline assessments. Major protocol deviations were
recorded in 706 patients in the ITT population, giving a PP
population of 210 patients. Despite this large discrepancy
in sample size, similar results were seen in both pop-
ulations for efficacy outcomes (Novartis data on file). The
safety population comprised 925 patients. Enrolment by
country was as follows: Argentina, 22 patients; Bulgaria,
12; Canada, 95; Cyprus, 20; Czech Republic, 114; Hungary,
60; The Netherlands, 156; Philippines, 1; Portugal, 62;
Russia, 65; Slovakia, 204; Slovenia, 11; Spain, 101; and
Taiwan, 20.
Five patients (0.5%) had previously been treated with
omalizumab (mean time to restarting treatment 33.86
months). Maintenance therapy at baseline consisted of OCS
monotherapy (28.4%), ICS monotherapy (26.5%), LABA
monotherapy (16.4%), ICS/LABA fixed-dose combination
therapy (82.1%), short-acting b2-agonist (SABA) mono-
therapy (5.1%), LAMA monotherapy (20.3%), SABA/LAMA
fixed-dose combination therapy (3.4%), leukotriene
inhibitors (61.4%) and other monotherapies (26.5%).
Mean total daily doses at baseline were 15.49 mgFigure 1 Patient disposition aprednisolone equivalent for OCS monotherapy and 1675 mg
beclomethasone dipropionate equivalent for ICS (mono-
therapy or combination therapy).
The individual last time-point (ILT; the time-point at
which the patient was last recorded as being on treatment)
was up to 24 months. Most (70.2%) of the ITT population had
an ILT at Month 24; 5.2%, 5.0%, 7.9%, 8.5% and 3.2% had an
ILT at 18 months, 12 months, 8 months, 16 weeks and at
baseline, respectively.
Physician’s Global Evaluation of Treatment
Effectiveness
For various reasons, including local label specifications,
GETE was not collected at the pre-specified Week 16 time-
point in all patients, but was collected at an earlier or
later time-point. Five hundred and eighty-four patients had
a GETE assessment at Week 16 (1 week); of these pa-
tients, 69.9% were considered responders (excellent/good
response) and 30.1% were non-responders (moderate/poor
response, or worsening asthma; Fig. 2a). At this time-point,
16 (1.7%) patients stopped treatment because they were
identified as non-responders by the physician. Data on GETE
evaluated at any time-point during the study were available
for 915 patients (Fig. 2b). Of these, 64.2% were classified as
responders, 30.7% were non-responders and 5.1% had no
GETE assessment. Asthma was considered to have worsened
in five patients (0.5%). Of the 210 patients in the PP pop-
ulation, 64.8% were responders on GETE evaluated at any
time-point during the study.
Exacerbations
The proportions of patients with no clinically significant or
severe clinically significant asthma exacerbations were
markedly higher at Months 12 and 24 than during thet Month 24 (end of registry).
Figure 2 Physician’s Global Evaluation of Treatment Effectiveness (GETE): (a) Week 16 measurements (1 week); (b) all
measurements. *Patients with an ‘excellent’ or ‘good’ response were considered responders; those with a ‘moderate’ or ‘poor’
response, and those with worsening of asthma, were considered non-responders.
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group of responders, the proportion of patients with no
clinically significant or severe clinically significant asthma
exacerbations was also markedly higher at Months 12 (82.4%
and 95.8%, respectively) and 24 (81.9% and 95.6%, respec-
tively) than during the 12-month pre-treatment period
(4.9% and 27.4%, respectively). Although not as marked,
similar findings were reported for severe clinically signifi-
cant asthma exacerbations among non-responders; 68.0%,
68.2% and 35.6% of non-responding patients had no
clinically significant asthma exacerbations at Month 12,
Month 24 and during the 12-month pre-treatment period,
respectively. Additionally, the mean annualised numbers
of clinically significant and severe clinically significant ex-
acerbations per patient in the ITT population wereconsiderably lower at Months 12 and 24 than the numbers
prior to treatment (Fig. 4).Symptoms and rescue medication use
In the week prior to the Month 12 and 24 time-points, a
lower proportion of patients had daytime symptoms, ac-
tivity limitations or nocturnal symptoms or awakenings, or
required rescue medication use, compared with baseline
(Table 2). At the Month 24 time-point, the number of days
in the previous week on which patients had experienced
each of these endpoints was less than half of the corre-
sponding baseline value. Similar results were seen in re-
sponders and non-responders, except for rescue medication
Figure 3 Percentage of patients with no exacerbations each time-point.
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4.9 days at baseline to 2.5 days at Month 24.
Lung function
Normal lung function (FEV1 80% predicted or personal
best) was observed in 37.7% (nZ 277/734) and 36.2% (233/
643) of patients in the week prior to the Month 12 and
Month 24 time-points, respectively, compared with 13.6%
(125/916) in the week prior to baseline. Mean (SD) FEV1Figure 4 Mean number of clinically significant and severe cl(% predicted) increased from baseline by 9.8% (18.1%) at
Month 12 and by 8.7% (18.5%) at Month 24. Mean (SD) PEF
increased from baseline by 40.4 (116.2) L/min at Month 12
and by 34.0 (132.2) L/min at Month 24.
Mean (SD) FEV1 (% predicted) increased from baseline by
10.3% (18.5%) at Month 12 and by 9.9% (19.8%) at Month 24
among responders, and by 8.8% (16.7%) and 5.5% (15.1%),
respectively, in non-responders. Mean (SD) PEF increased
from baseline by 44.7 (122.0) L/min at Month 12 and by 37.3
(144.2) L/min at Month 24 among responders, and byinically significant exacerbations. Error bars represent SD.
Table 2 Asthma symptoms, activity limitations, and rescue medication use. Except where otherwise stated, data relate to the
week immediately prior to each of the stated time-points (ITT population).
Baseline (N Z 916) Month 12 (N Z 734) Month 24 (N Z 643)
Daytime symptoms
Patients, n (%) 829 (90.5) 422 (57.5) 348 (54.1)
Number of days, mean (SD) 5.0 (2.28) 1.7 (2.14) 1.6 (2.20)
Change in number of days, mean (SD) e 3.3 (2.74) 3.4 (2.76)
Limitations of activities
Patients, n (%) 788 (86.0) 342 (46.6) 268 (41.7)
Number of days, mean (SD) 4.4 (2.44) 1.3 (1.94) 1.2 (1.96)
Change in number of days, mean (SD) e 3.1 (2.61) 3.2 (2.71)
Nocturnal symptoms or awakenings
Patients, n (%) 729 (79.6) 225 (30.7) 163 (25.3)
Number of days, mean (SD) 3.3 (2.37) 0.7 (1.41) 0.6 (1.43)
Change in number of days, mean (SD) e 2.6 (2.62) 2.8 (2.47)
Rescue medication use
Patients, n (%) 797 (87.0) 397 (54.1) 320 (49.8)
Number of days, mean (SD) 4.8 (2.49) 1.8 (2.35) 1.6 (2.31)
Change in number of days, mean (SD) e 3.0 (2.91) 3.2 (2.85)
SD Z standard deviation.
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non-responders.
Asthma control and asthma-related quality of life
Based on investigator assessment, a higher percentage of
patients had controlled or partly controlled asthma in the
week prior to Months 12 and 24 than was noted at baseline
(85.0% and 87.1%, respectively, versus 24.2%).
Asthma control, as measured by the ACT or ACQ, also
improved post-treatment (Table 3). On average, a mean-
ingful improvement in ACT score (i.e. an increase of 3
points versus baseline) was seen from baseline to Months 12
and 24 (change in score 6.1 and 6.2, respectively). Clini-
cally relevant improvements (i.e. a decrease of 0.5 points
versus baseline) of 0.83 and 0.80 were also seen in the
ACQ score at Months 12 and 24, respectively. There was also
a mean improvement from baseline in the AQLQ scores at
Months 12 and 24 (Table 3), with clinically relevant (0.5
point) improvements seen in 67.2% of patients at Month 12
and 60.7% at Month 24. Similar findings were reported for
mini-AQLQ scores.
Among the subgroup of responders, findings were similar
to those reported for the whole ITT population. On
average, among non-responders, a reduced but still
meaningful improvement in ACT score was seen from
baseline to Months 12 and 24 (change in score 4.9 and 5.2,
respectively). A clinically relevant improvement of 0.66
was also seen in the ACQ score at Month 24. Of the patients
who completed the AQLQ and mini-AQLQ at baseline, 12
months and 24 months, the majority had a clinically rele-
vant improvement of 0.5 points.
Healthcare utilisation and missed work/school days
Healthcare utilisation and absences from work or school
were reduced during omalizumab treatment. Mean (SD)annualised numbers of asthma-related medical health-
care uses (hospitalisations, ER visits and unscheduled
doctor visits) per patient were 1.0 (1.96) at Month 12 and
0.5 (1.28) at Month 24, lower than during the 12-month
pre-treatment period (6.2 [6.97]). The mean (SD)
annualised numbers of days of missed work due to
asthma were 3.5 (17.28) and 1.0 (4.66) at Months 12 and
24, respectively, substantially less than during the pre-
treatment period (26.4 [49.61] days). Similarly, the mean
(SD) numbers of days of missed school due to asthma at
Months 12 and 24 were 1.6 (4.28) and 1.9 (5.46),
respectively, compared with 20.7 (27.49) days during the
pre-treatment period. Marked reductions in healthcare
utilisation and numbers of days of missed work or school
due to asthma were reported in both responders and
non-responders.OCS use
The proportion of patients taking maintenance OCS therapy
was lower at Month 24 (14.2%) than at Month 12 (16.1%) and
baseline (28.6%). In addition, the mean (SD) total daily OCS
dose (in prednisolone-equivalent mg) decreased markedly
between baseline [15.5 (14.0) mg] and Month 12 [7.7
(10.9) mg], and was reduced further by Month 24 [5.8
(8.9) mg]. Similar findings were reported for the subgroup
of responders: the proportion of patients taking mainte-
nance OCS therapy was lower at Month 24 (12.1%) than at
Month 12 (13.8%) and baseline (28.1%). Among non-
responders, the proportion of patients taking mainte-
nance OCS therapy was lower at Month 24 (17.9%) than at
Month 12 (20.9%) and baseline (28.5%).
Among patients in the ITT population receiving OCS at
baseline, there was a reduction in OCS dose or discon-
tinuation of OCS treatment in 57.1% and 69.0% of pa-
tients at Months 12 and 24, respectively. A minority of
patients at Month 12 (n Z 5; 2.6%) at Month 24 (n Z 4;
Table 3 Results for the Asthma Control Test (ACT), asthma control questionnaire (ACQ) and standard and abbreviated
Asthma Quality-of-Life Questionnaires (AQLQ and mini-AQLQ, respectively) (ITT population).
Questionnaire Baseline (N Z 916) Month 12 (N Z 734) Month 24 (N Z 643)
ACTa
Overall score
n 496 417 361
Mean (SD) 13.0 (4.58) 19.1 (4.40) 19.7 (4.45)
Change from baseline
n e 342 292
Mean (SD) e 6.1 (5.37) 6.2 (5.56)
ACQb
Overall score
n 181 94 62
Mean (SD) 2.74 (0.97) 1.73 (1.12) 1.80 (1.07)
Change from baseline
n e 80 52
Mean (SD) e 0.83 (1.20) 0.80 (1.19)
AQLQa
Overall score
n 132 92 81
Mean (SD) 4.27 (1.27) 5.58 (1.06) 5.49 (1.30)
Change from baseline
n e 64 56
Mean (SD) e 0.97 (0.97) 0.75 (1.09)
Mini-AQLQa
Overall score
n 204 163 125
Mean (SD) 3.81 (1.19) 5.04 (1.33) 5.20 (1.30)
Change from baseline
n e 135 104
Mean (SD) e 1.30 (1.43) 1.62 (1.40)
SD Z standard deviation.
a Increase in score reflects an improvement.
b Decrease in score reflects an improvement.
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baseline.
Serious adverse events
Nine deaths occurred during the registry, none of which
were suspected to be related to omalizumab. There was
one death each due to cardiac failure, malignant lung
neoplasm, chronic obstructive pulmonary disease exacer-
bation, sudden death, cholestatic jaundice, progression of
asthma and respiratory failure, and two deaths due to
sepsis. One hundred and fifty SAEs were reported by 64
patients (6.9%; Table 4). The most common SAE was asthma
(32 patients, 3.5%), followed by dyspnoea and pneumonia
(each in 7 patients, 0.8%). Other SAEs were reported mostly
for single patients, including one case of anaphylaxis sus-
pected to be due to omalizumab. Thirty-eight patients
discontinued omalizumab due to SAEs. Overall, 25 (16.7%)
of the total 150 SAEs were suspected to be related to
omalizumab, most commonly dyspnoea, sudden chest
tightness and headache (3 events each). Of these, 14 SAEs
(in five patients) led to permanent discontinuation of
omalizumab and two SAEs led to temporary dosageinterruption. For the remaining nine SAEs, no action was
taken with regard to omalizumab treatment.Discussion
The two-year eXpeRience registry enabled the collection
and analysis of real-world data on outcomes in patients
receiving omalizumab for uncontrolled allergic asthma.
Baseline characteristics from 294 participants were re-
ported previously25 and highlighted the need for improved
asthma control in this group of patients.
The results of this analysis indicate that a significant
proportion of patients on omalizumab therapy responded
well to treatment, with investigators rating the majority of
patients (69.9%) as responders (16-week GETE assessment
excellent/good). Similar results have been seen in clinical
trials, in which 53%e60% of omalizumab-treated patients
had an excellent/good response, compared with 33%e42%
for placebo.7,11 Real-world studies in smaller patient pop-
ulations treated for shorter durations have reported
excellent or good responses in 68%e89.1% of patients.26e32
However, the eXpeRience registry is considerably larger,
Table 4 Serious adverse events (SAEs) in patients
(N Z 925)a receiving omalizumab therapy.
Patients with any SAE(s) e n (%) 64 (6.9)
Total number of reported SAEs 150
Relationship to omalizumab (suspected) e
n (%) of events
25 (16.7%)
No change in dosage 9 (36.0%)
Dosage temporarily interrupted 2 (8.0%)
Permanently discontinued 14 (56.0%)
Omalizumab-related SAEs (suspected) by primary
system organ class and preferred term e n (%)
Congenital, familial and genetic disorders 1 (4.0%)
Transposition of the great vessels 1 (4.0%)
Gastrointestinal disorders 1 (4.0%)
Dry mouth 1 (4.0%)
General disorders and
administration side conditions
4 (16.0%)
Chest discomfort 3 (12.0%)
Oedema 1 (4.0%)
Immune system disorders 1 (4.0%)
Anaphylactic reaction 1 (4.0%)
Infections and infestations 1 (4.0%)
Sepsis 1 (4.0%)
Injury, poisoning and procedural
complications
1 (4.0%)
Oxygen saturation decreased 1 (4.0%)
Nervous system disorders 5 (20.0%)
Dizziness 1 (4.0%)
Headache 3 (12.0%)
Tremor 1 (4.0%)
Pregnancy, puerperium and
perinatal conditions
3 (12.0%)
Abortion missed 1 (4.0%)
Abortion spontaneous 1 (4.0%)
Intra-uterine death 1 (4.0%)
Respiratory, thoracic and
mediastinal disorders
6 (24.0%)
Asthma 1 (4.0%)
Dyspnoea 3 (12.0%)
Dyspnoea at rest 1 (4.0%)
Pulmonary embolism 1 (4.0%)
Skin and subcutaneous
tissue disorders
1 (4.0%)
Hyperhidrosis 1 (4.0%)
Vascular disorders 2 (8.0%)
Flushing 1 (4.0%)
Hypotension 1 (4.0%)
SAEs occurring at any time during the registry are presented.
a Represents safety population and includes all patients
enrolled in the registry who received at least one dose of
omalizumab and had at least one post-baseline safety
assessment.
Omalizumab e eXpeRience registry 2-year results 1149has a longer duration of follow-up and included more as-
sessments than many of these previous studies. A 4-year
omalizumab treatment real-world study has demonstrated
significant improvements in lung function and other out-
comes, but was conducted in a very small number of
patients.33In the present study, 1e2 yrs of treatment with omali-
zumab was associated with reductions in daytime symp-
toms, activity limitations, nocturnal symptoms/awakening,
and rescue medication use. The overall frequencies of
these outcomes were similar to those reported in a real-
world study in Germany.34 The eXpeRience registry also
revealed substantial reductions in clinically significant
asthma exacerbations, including those classified as severe,
after 1 and 2 yrs of omalizumab treatment. Lung function
(FEV1 [% predicted] and PEF) improved at both time-points
(Months 12 and 24) compared with pre-treatment values.
Furthermore, omalizumab was associated with reductions
in healthcare utilisation and in absence from work or school
at all time-points versus baseline. These findings suggest
that treatment with omalizumab may have a significant
impact on the direct and indirect costs of illness in these
patients. Improvements in asthma control (ACT and ACQ)
and asthma-related quality of life (AQLQ and mini-AQLQ),
as well as reductions in OCS use, were also observed.
Patients included in the eXpeRience registry were
generally more heterogeneous (in terms of the frequency of
asthma symptoms and exacerbations, lung function and
frequent requirements for medical intervention) compared
with subjects enrolled in controlled clinical trials. The
difficulties of achieving control in asthma have been high-
lighted by the GOAL study,35 in which approximately 30% of
patients who received stepwise treatment with salmeterol/
fluticasone for 1 yr (with or without prednisolone) did not
achieve asthma control. Our results suggest that the addi-
tion of omalizumab to existing treatment may improve
outcomes in this setting, and we propose that the findings
of the eXpeRience registry are applicable to the general
population of patients with uncontrolled persistent allergic
asthma, despite following guideline-based background
therapies.
In addition, our data are consistent with those from
several pivotal clinical trials5e14 and real-world studies26e33
that predominantly enrolled populations with uncontrolled
severe allergic asthma. Direct comparisons between our
results and those of randomised controlled trials should be
made with caution because of differences in trial design and
duration, and in the definitions of some outcome measures.
No unexpected safety issues were identified during the
eXpeRience registry. None of the nine deaths was suspected
to be related to omalizumab, and the number of SAEs
considered to be treatment-related was low. The frequency
of SAEs in eXpeRience was comparable to that seen in
controlled trials of omalizumab.36
As with all observational studies, the results should be
interpreted with due consideration that factors other than
the treatment of interest may have contributed to the
findings. Other potential limitations include the fact that
patient selection and continuation on omalizumab beyond
16 weeks was at the discretion of the treating physician,
and that the indications for treatment vary between
countries. A significant proportion of patients (16.6%) dis-
continued treatment, for various reasons, but this is likely
to reflect the real-world situation. Finally, the relative
infrequency of data collection introduces the potential for
recall bias.
Despite these limitations, the concordance between our
results and those of randomised controlled trials suggests
1150 G.-J. Braunstahl et al.that the observed improvements in asthma control, number
and severity of exacerbations, symptoms, lung function and
healthcare utilisation were in all likelihood due to treat-
ment with omalizumab.
In conclusion, results from the 2-year eXpeRience reg-
istry support findings from randomised trials that omalizu-
mab significantly improves asthma control when added to
current therapy in patients with uncontrolled persistent
allergic asthma.
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